INO Inovio Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: INO
Price (delayed)
$2.29
Market cap
$121.7M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.61
Enterprise value
$108M
Relative Growth:
16
Relative Strength:
72
Relative Valuation:
1
Relative Profitability:
32
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO
Highlights
INO's EPS is up by 49% year-on-year and by 18% since the previous quarter
INO's net income is up by 28% year-on-year and by 9% since the previous quarter
The equity has plunged by 71% YoY and by 44% from the previous quarter
INO's revenue has dropped by 69% year-on-year and by 36% since the previous quarter
Key stats
What are the main financial stats of INO
Market
Valuations
Earnings
Shares outstanding
53.14M
Market cap
$121.7M
Enterprise value
$108M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.94
Price to sales (P/S)
487.67
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
592.33
Revenue
$182,337
Gross profit
$182,337
Operating income
-$95.85M
Net income
-$87.76M
EBIT
-$87.76M
EBITDA
-$84.73M
Free cash flow
-$94.82M
Per share
Balance sheet
Liquidity
EPS
-$2.61
EPS diluted
-$2.61
Free cash flow per share
-$2.44
Book value per share
$0.78
Revenue per share
$0
TBVPS
$1.76
Total assets
$68.24M
Total liabilities
$39.71M
Debt
$10.66M
Equity
$28.53M
Working capital
$20.99M
Debt to equity
0.37
Current ratio
1.66
Quick ratio
1.53
Net debt/EBITDA
0.16
Margins
Efficiency
Dividend
EBITDA margin
-46,471.3%
Gross margin
100%
Net margin
-48,131.4%
Operating margin
-52,568.6%
Return on assets
-93.4%
Return on equity
-158.3%
Return on invested capital
-230.4%
Return on capital employed
-240.2%
Return on sales
-48,131.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INO stock price
How has the Inovio Pharmaceuticals stock price performed over time
Intraday
-5.76%
1 week
-5.76%
1 month
-5.76%
1 year
-59.25%
YTD
25.14%
QTD
-2.14%
Financial performance
How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$182,337
Gross profit
$182,337
Operating income
-$95.85M
Net income
-$87.76M
Gross margin
100%
Net margin
-48,131.4%
The company's operating margin has shrunk by 144% YoY and by 40% QoQ
Inovio Pharmaceuticals's net margin has shrunk by 134% YoY and by 41% QoQ
INO's revenue has dropped by 69% year-on-year and by 36% since the previous quarter
The gross profit has dropped by 69% year-on-year and by 36% since the previous quarter
Price vs fundamentals
How does INO's price correlate with its fundamentals
Growth
What is Inovio Pharmaceuticals's growth rate over time
Valuation
What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.94
P/S
487.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
592.33
INO's EPS is up by 49% year-on-year and by 18% since the previous quarter
The stock's price to book (P/B) is 95% more than its last 4 quarters average of 1.6 and 49% more than its 5-year quarterly average of 2.1
The equity has plunged by 71% YoY and by 44% from the previous quarter
The P/S is 90% higher than the 5-year quarterly average of 272.5 and 23% higher than the last 4 quarters average of 420.9
INO's revenue has dropped by 69% year-on-year and by 36% since the previous quarter
Efficiency
How efficient is Inovio Pharmaceuticals business performance
INO's return on sales has dropped by 136% year-on-year and by 41% since the previous quarter
The company's return on invested capital has shrunk by 134% YoY and by 29% QoQ
INO's ROE is down by 45% YoY and by 19% from the previous quarter
INO's return on assets is down by 20% year-on-year and by 7% since the previous quarter
Dividends
What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INO.
Financial health
How did Inovio Pharmaceuticals financials performed over time
The total assets is 72% greater than the total liabilities
INO's quick ratio has dropped by 64% year-on-year and by 40% since the previous quarter
INO's current ratio has shrunk by 63% YoY and by 37% QoQ
Inovio Pharmaceuticals's debt is 63% lower than its equity
The debt to equity has soared by 185% YoY and by 68% from the previous quarter
The equity has plunged by 71% YoY and by 44% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.